News & Updates

Baseline eGFR predicts inhibitor-induced AKI

26 Apr 2024

A recent study has found three baseline characteristics that can predict sustained acute kidney injury (AKI), and these include estimated glomerular filtration rate (eGFR), loop diuretic, and spironolactone use. For immune checkpoint inhibitor-related AKI, only baseline eGFR is predictive.

Baseline eGFR predicts inhibitor-induced AKI

26 Apr 2024

Intranasal zavegepant offers freedom from pain in women with acute migraine

26 Apr 2024 by

The use of nasal spray zavegepant 10 mg provides freedom from pain and the most bothersome migraine symptom (MBS*) at 2 hours after treatment in women with acute migraine, according to the pooled analysis of the two trials presented at AAN 2024.

Intranasal zavegepant offers freedom from pain in women with acute migraine

26 Apr 2024

Stand Against Prediabetes campaign aiming for early detection, better management

26 Apr 2024 by

The ‘Stand Against Prediabetes; Don’t Sugarcoat It’ (SAPd) program was recently launched in Putrajaya.

Stand Against Prediabetes campaign aiming for early detection, better management

26 Apr 2024

Pharmacist-driven program viable in patients taking antineoplastic agents

25 Apr 2024

A pharmacist monitoring program is feasible and useful for patients receiving oral antineoplastic agents, reports a recent study.

Pharmacist-driven program viable in patients taking antineoplastic agents

25 Apr 2024

Ecopipam cuts Tourette tics

25 Apr 2024 by

Children and adolescents with Tourette syndrome (TS) may benefit from ecopipam, a first-in-class selective dopamine-1 (D1) receptor antagonist, as it reduced the number of tics and level of daily interference in a post hoc analysis of the phase IIb D1AMOND trial.

Ecopipam cuts Tourette tics

25 Apr 2024

‘Inclisiran first’ strategy in ASCVD reduces LDL-C

25 Apr 2024 by

Among patients with atherosclerotic cardiovascular disease (ASCVD) who fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals despite receiving maximally tolerated statins, initiating inclisiran immediately resulted in significant reductions in LDL-C, according to the VICTORION-INITIATE trial presented at ACC.24.

‘Inclisiran first’ strategy in ASCVD reduces LDL-C

25 Apr 2024

Web-based app to guide nonprescription use of statins a win in TACTiC trial

24 Apr 2024 by

Self-selecting for nonprescription statin therapy with the help of a Web-based application leads to a high percentage of individuals correctly confirming their eligibility, using the medication appropriately, and achieving significant low-density lipoprotein cholesterol (LDL-C) reductions, according to the results of the TACTiC trial.

Web-based app to guide nonprescription use of statins a win in TACTiC trial

24 Apr 2024

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

24 Apr 2024

In the treatment of radiographic axial spondyloarthritis (r-axSpA), the 2-year incidence of spinal radiographic progression is low and not different between secukinumab and adalimumab biosimilar, as shown in the phase IIIb study SURPASS study.

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

24 Apr 2024

Investigational agent works well for migraine in pooled analysis

24 Apr 2024 by

Treatment with the investigational agent AXS-07 significantly alleviates pain and most bothersome symptoms (MBS) in patients with migraine, according to results of a pooled analysis of the phase III MOMENTUM and INTERCEPT trials presented at AAN 2024.

Investigational agent works well for migraine in pooled analysis

24 Apr 2024

SGLT2 inhibitors a promising gout medication in T2D

23 Apr 2024 by

The use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors lowers the risk of incident gout or recurrent gout flares among patients with type 2 diabetes who are taking metformin, as shown in a study.

SGLT2 inhibitors a promising gout medication in T2D

23 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

Baseline eGFR predicts inhibitor-induced AKI

Baseline eGFR predicts inhibitor-induced AKI

Intranasal zavegepant offers freedom from pain in women with acute migraine

Intranasal zavegepant offers freedom from pain in women with acute migraine

Stand Against Prediabetes campaign aiming for early detection, better management

Stand Against Prediabetes campaign aiming for early detection, better management

Pharmacist-driven program viable in patients taking antineoplastic agents

Pharmacist-driven program viable in patients taking antineoplastic agents

Ecopipam cuts Tourette tics

Ecopipam cuts Tourette tics

‘Inclisiran first’ strategy in ASCVD reduces LDL-C

‘Inclisiran first’ strategy in ASCVD reduces LDL-C

Web-based app to guide nonprescription use of statins a win in TACTiC trial

Web-based app to guide nonprescription use of statins a win in TACTiC trial

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

Investigational agent works well for migraine in pooled analysis

Investigational agent works well for migraine in pooled analysis

SGLT2 inhibitors a promising gout medication in T2D

SGLT2 inhibitors a promising gout medication in T2D